Drugs / BE1116
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07094087 | Sep 2025 → Nov 2026 expected | — | CSL Behring | Recruiting | No outcome recorded |
| Phase 3 | NCT05568888 | Mar 2023 → Oct 2024 | — | CSL Behring | Terminated | No outcome recorded |
| Phase 3 | NCT02281201 | Oct 2014 → Jan 2016 | — | CSL Behring | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BE1116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07094087 ↗ |
| Action | Restore | “correcting coagulation factor deficiencies” NCT07094087 ↗ |
| Modality | Protein / enzyme biologic | “Biological: BE1116 (Prothrombin Complex Concentrate)” NCT02281201 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05568888 ↗ |